Ranibizumab SPC Cut By Nearly Two Years In UK
Filing Error Slices Nearly Two Years Off Roche’s UK Lucentis Protection
Executive Summary
A ruling by the High Court has cut almost two years from UK SPC protection for Roche's Lucentis ranibizumab brand, potentially offering biosimilar competitors the change to jump into the market early.
You may also be interested in...
UK Lucentis Biosimilar Nod Offers Teva Potential First-Mover Advantage
Teva is gearing up to introduce the Ongavia ranibizumab biosimilar in the UK, following an approval by the local regulator ahead of its European counterpart. The development means the Israeli firm and partners Bioeq and Formycon could secure a global first launch of a rival to Lucentis, ahead of expected imminent launches by Samsung Bioepis of its Byooviz version in the US and Europe.
UK Lucentis Biosimilar Nod Offers Teva Potential First-Mover Advantage
Teva is gearing up to introduce the Ongavia ranibizumab biosimilar in the UK, following an approval by the local regulator ahead of its European counterpart. The development means the Israeli firm and partners Bioeq and Formycon could secure a global first launch of a rival to Lucentis, ahead of expected imminent launches by Samsung Bioepis of its Byooviz version in the US and Europe.
Formycon Delay Pushes Back Coherus’ Ranibizumab
Formycon and Bioeq’s US filing for a biosimilar ranibizumab rival to Lucentis has been delayed after the FDA requested further data following a manufacturing change. Rights to the biosimilar have been licensed exclusively to Coherus in the US.